SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Capital World Investors – ‘SC 13G/A’ on 6/10/08 re: Endo Health Solutions Inc.

On:  Tuesday, 6/10/08, at 1:56pm ET   ·   Accession #:  1422849-8-385   ·   File #:  5-59365

Previous ‘SC 13G’:  ‘SC 13G/A’ on 4/10/08   ·   Next:  ‘SC 13G/A’ on 6/10/08   ·   Latest:  ‘SC 13G/A’ on 3/8/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer

 6/10/08  Capital World Investors           SC 13G/A               1:8K   Endo Health Solutions Inc.

Amendment to Statement of Beneficial Ownership   —   Schedule 13G
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: SC 13G/A    Amendment to Statement of Beneficial Ownership         5     18K 


Document Table of Contents

Page (sequential) | (alphabetic) Top
 
11st Page   -   Filing Submission
3Item 1(a). Name of Issuer: Endo Pharmaceuticals Holdings Inc
"Item 2(a). Name of Person(s) Filing: Capital World Investors
"Item 2(c). Citizenship: N/A
"Item 2(d). Title of Class of Securities: Common Stock
"Item 2(e). CUSIP Number: 29264F205
"Item 4. Ownership
4Item 8. Identification and Classification of Members of the Group: N/A
"Item 9. Notice of Dissolution of Group: N/A
"Item 10. Certification
SC 13G/A1st Page of 5TOCTopPreviousNextBottomJust 1st
 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Endo Pharmaceuticals Holdings Inc (Name of Issuer) Common Stock (Title of Class of Securities) 29264F205 (CUSIP Number) May 30, 2008 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP: 29264F205 Page 1 of 5
SC 13G/A2nd Page of 5TOC1stPreviousNextBottomJust 2nd
1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Capital World Investors ** 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware 5 SOLE VOTING POWER 7,550,000 6 SHARED VOTING POWER NUMBER OF SHARES NONE BENEFICIALL Y OWNED BY 7 SOLE DISPOSITIVE POWER EACH REPORTING 12,850,000 PERSON WITH: 8 SHARED DISPOSITIVE POWER NONE 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 12,850,000 Beneficial ownership disclaimed pursuant to Rule 13d-4 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 10.6% 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IA ** A division of Capital Research and Management Company (CRMC) CUSIP: 29264F205 Page 2 of 5
SC 13G/A3rd Page of 5TOC1stPreviousNextBottomJust 3rd
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Schedule 13G Under the Securities Exchange Act of 1934 Amendment No. 1 Item 1(a) Name of Issuer: Endo Pharmaceuticals Holdings Inc Item 1(b) Address of Issuer's Principal Executive Offices: 100 Endo Blvd Chadds Ford PA 19317 Item 2(a) Name of Person(s) Filing: Capital World Investors Item 2(b) Address of Principal Business Office or, if none, Residence: 333 South Hope Street Los Angeles, CA 90071 Item 2(c) Citizenship: N/A Item 2(d) Title of Class of Securities: Common Stock Item 2(e) CUSIP Number: 29264F205 Item 3 If this statement is filed pursuant to sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (e) [X] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E). Item 4 Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: (b) Percent of class: (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: (ii) Shared power to vote or to direct the vote: (iii) Sole power to dispose or to direct the disposition of: (iv) Shared power to dispose or to direct the disposition of: See page 2 Capital World Investors is deemed to be the beneficial owner of 12,850,000 shares or 10.6% of the 121,776,254 shares of Common Stock believed to be outstanding as a result of CRMC acting as investment adviser to various investment companies registered under Section 8 of the Investment Company Act of 1940. CUSIP: 29264F205 Page 3 of 5
SC 13G/A4th Page of 5TOC1stPreviousNextBottomJust 4th
Item 5 Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ] Item 6 Ownership of More than Five Percent on Behalf of Another Person: One or more clients of Capital World Investors have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock of Endo Pharmaceuticals Holdings Inc. Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. : N/A Item 8 Identification and Classification of Members of the Group: N/A Item 9 Notice of Dissolution of Group: N/A Item 10 Certification By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: June 10, 2008 Signature: Robert W. Lovelace*** Name/Title: Robert W. Lovelace - Senior Vice President Capital World Investors ***By /s/ Donald H. Rolfe Donald H. Rolfe Attorney-in-fact Signed pursuant to a Power of Attorney dated December 21, 2007 included as an Exhibit to Schedule 13G filed with the Securities and Exchange Commission by Capital World Investors on January 10, 2008 with respect to Lowes Companies, Incorporated. CUSIP: 29264F205 Page 4 of 5
SC 13G/ALast Page of 5TOC1stPreviousNextBottomJust 5th
CUSIP: 29264F205 Page 5 of 5

Dates Referenced Herein   and   Documents Incorporated by Reference

Referenced-On Page
This ‘SC 13G/A’ Filing    Date First  Last      Other Filings
Filed on:6/10/084SC 13G/A
5/30/081
1/10/084SC 13G
12/21/074SC 13D/A
 List all Filings 
Top
Filing Submission 0001422849-08-000385   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 9:01:17.2am ET